miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia
miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia
复制标题
DOI：
10.1182/blood-2011-01-333484
复制
发表时间：
2011-09-15
期刊：
影响因子：
20.3
通讯作者：
Croce, Carlo M.
中科院分区：
文献类型：
--
作者：
Visone, Rosa;Veronese, Angelo;Croce, Carlo M.
MicroRNAs在慢性淋巴细胞白血病中起着至关重要的作用。我们调查了microRNAs是否可以区分进展性疾病患者和稳定期疾病患者。我们分析了从114名稳定期或进展期患者的358份连续样本中分离的白血病细胞上的microRNA表达。我们发现，在疾病过程中，随着时间的推移，进行性(P<；.001，训练和验证集)患者样本(P<；.001，训练和验证集)的miR-181b的表达值下降，而稳定疾病(P=0.3，训练集；P=.2，验证集)患者的样本中，miR-181b的表达值下降。顺序样本和/或miR-181b值之间的>；=50%的下降
MicroRNAs play a crucial role in chronic lymphocytic leukemia. We investigated whether microRNAs can discriminate patients with a progressive disease from patients with a stable disease. We analyzed microRNA expression on leukemic cells isolated from 358 sequential samples of 114 patients with either stable or progressive disease. We found that during the course of the disease the expression values of miR-181b, the most dysregulated microRNA, decreased in samples of patients with a progressive (P < .001, training and validation sets) but not in samples of patients with a stable disease (P = .3, training set; P = .2, validation set) over time. A drop of >= 50% between sequential samples and/or a miR-181b value